<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To determine the prevalence and spectrum of underlying <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e>, especially <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sjögren's syndrome</z:e> (SS) and the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, and the prevalence of the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, antinuclear antibody (ANA), and rheumatoid factor (RF) within a neurologic patient population </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: The study design entailed a prospective, consecutive sample of patients admitted to a university-affiliated neurology service for 72 hours or more </plain></SENT>
<SENT sid="2" pm="."><plain>Study patients were obtained from a sequential evaluation of 100 inpatients with a wide spectrum of <z:e sem="disease" ids="C1456669" disease_type="Disease or Syndrome" abbrv="">neurologic diseases</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Another 31 eligible patients were not included due to refusal (n = 4), inability to give consent (n = 12), or an incomplete database (n = 15) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent a physical examination and responded to a <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic disease</z:e> questionnaire (administered by one rheumatologist) assessing signs and symptoms relevant to <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> had <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, ANA, and RF determinations </plain></SENT>
<SENT sid="6" pm="."><plain>An independent patient evaluation was done by the attending neurologist </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Eleven patients had a rheumatic or <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> directly related to their neurologic admission: three patients with SS (one each with embolic <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0000726'>dementia</z:hpo>, and hemiparetic <z:e sem="disease" ids="C0149779" disease_type="Mental or Behavioral Dysfunction" abbrv="">somatization</z:e>); three patients with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> syndrome (<z:hpo ids='HP_0000001'>all</z:hpo> with <z:hpo ids='HP_0001297'>stroke</z:hpo>, recurrent in two); one patient with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> accompanied by <z:hpo ids='HP_0002076'>migraine headache</z:hpo> and the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>; and one patient each with isolated central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) <z:mp ids='MP_0001864'>angiitis</z:mp>, neuro-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:e sem="disease" ids="C0023788" disease_type="Disease or Syndrome" abbrv="">Whipple's disease</z:e>, and HLA-B27-associated <z:e sem="disease" ids="C0949691" disease_type="Disease or Syndrome" abbrv="SPDA1">spondyloarthropathy</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Nineteen patients had one or more autoantibodies: ANA greater than or equal to 1:80 (n = 10); RF greater than or equal to 1:80 (n = 6); and positive <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (n = 7) </plain></SENT>
<SENT sid="9" pm="."><plain>The seroreactivity of 10 of these patients remained unexplained </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: This neurologic population demonstrated significant seroreactivity and <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic disease</z:e> associations, with SS and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>-related neurologic disease the most common </plain></SENT>
<SENT sid="11" pm="."><plain>Since SS and the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> can be overlooked, it is recommended that a formal evaluation for SS and a direct <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> assay should be considered in the examination of patients with neuropsychiatric symptoms </plain></SENT>
</text></document>